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ABSTRACT
Replication protein A (RPA), essential for DNA repli-
cation, repair and DNA damage signalling, posse-
sses six ssDNA-binding domains (DBDs), including
DBD-F on the N-terminus of the largest subunit,
RPA70. This domain functions as a binding site for
p53 and other DNA damage and repair proteins that
contain amphipathic alpha helical domains. Here,
we demonstrate direct binding of both ssDNA and
the transactivation domain 2 of p53 (p53TAD2) to
DBD-F, as well as DBD-F-directed dsDNA strand
separation by RPA, all of which are inhibited by
fumaropimaric acid (FPA). FPA binds directly to
RPA, resulting in a conformational shift as
determined through quenching of intrinsic trypto-
phan fluorescence in full length RPA. Structural
analogues of FPA provide insight on chemical
properties that are required for inhibition. Finally,
we confirm the inability of RPA possessing R41E
and R43E mutations to bind to p53, destabilize
dsDNA and quench tryptophan fluorescence by
FPA, suggesting that protein binding, DNA modula-
tion and inhibitor binding all occur within the same
site on DBD-F. The disruption of p53–RPA inter-
actions by FPA may disturb the regulatory functions
of p53 and RPA, thereby inhibiting cellular pathways
that control the cell cycle and maintain the integrity
of the human genome.
INTRODUCTION
Genome stability requires the interplay of many signalling
and DNA repair pathways, often requiring the action
and regulation of multifunctional proteins that can
modulate their activities appropriately during periods of
DNA replication stress. Replication protein A (RPA),
the major single-stranded DNA (ssDNA)-binding
protein in eukaryotic cells, coordinates multiple DNA
metabolic functions through interactions with numerous
proteins critical to the DNA damage response (DDR)
and DNA repair (1). RPA consists of three subunits
(RPA70, RPA32 and RPA14) encompassing five
ssDNA-binding domains (DBDs) that contribute to the
high affinity of RPA binding to ssDNA (Figure 1) (2).
RPA also has an affinity for dsDNA. In vitro experiments
have shown that RPA binds to dsDNA and destabilizes
the double helix, resulting in strand separation and
RPA binding to ssDNA (3–5). The sixth identified
binding domain, DBD-F, located on the N-terminus of
RPA70, has been identified as the DBD primarily respon-
sible for this destabilization activity of dsDNA (4).
Although the precise mechanism of helix destabilization
is not fully understood, the ability of DBD-F to bind
ssDNA independently of the other DBDs with low
affinity may be relevant to RPA unwinding activity (6).
Additionally, DBD-F is a protein–protein interaction
domain that is important in DNA repair and cell cycle
checkpoint activities. A DBD-F mutant strain in yeast,
rfa-t11, was found to be replication competent, but hom-
ologous recombination (HR) and checkpoint defective,
suggesting that DBD-F was essential for specific DNA
repair and the DDR signalling pathways, but not essential
for replication in unstressed cells (7,8). Transient siRNA
studies confirmed the importance of this domain in the
DDR, as human cells expressing RPA70 with the analo-
gous rfa-t11 mutation resulted in replication comparable
with cells expressing wt-RPA70; however, they were sen-
sitive to camptothecin- and etoposide-induced replication
stress (9,10).
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The significance of DBD-F as a domain for protein–
protein interactions was first described through an associ-
ation with p53 (11–13). More recently, studies revealed
that checkpoint activation, in part, is mediated through
the recruitment of checkpoint proteins Rad9, ATR
interacting protein (ATRIP) and Mre11 by DBD-F, as
these proteins contain an amphipathic alpha helical
domain that binds to the basic cleft of DBD-F (14–16).
With the emergence of DBD-F as a recruiting scaffold for
the assembly of DDR proteins, we have been interested in
this domain as a novel target for cancer therapy, leading
to our previous discovery of fumaropimaric acid (FPA) as
an inhibitor of RPA protein interactions (17).
Tumour suppressor p53, the most commonly mutated
gene in human cancers, primarily regulates the transcrip-
tion of numerous genes involved in cell cycle control,
apoptosis and DNA repair (18,19). p53 functions as a
homotetramer and consists of DNA-binding and
tetramerization domains that are flanked by two intrinsic-
ally disordered regions at both the N- and C-termini, the
N-terminal transactivation and C-terminal regulatory
domains, respectively (20). The N-terminal transactivation
domain can be further divided into two subdomains,
TAD1 (amino acids 1–40) and TAD2 (amino acids
41–61) (21). As TAD2 comes in contact with proteins
containing DNA-binding domains, this intrinsically
disordered region conforms to an amphipathic a-helix
upon binding to proteins such as RPA (13,22). The
p53TAD2 behaves as a ssDNA mimetic competing with
ssDNA for binding to the DNA binding oligonucleotide/
oligosaccharide-binding (OB) folds located within BRCA2
and RPA (23,24). Sequestration of p53 by BRCA2 and
RPA has been suggested to inhibit the transcriptional
activity of p53 with consequent down-regulation of apop-
tosis (25,26). Evidence for this model was demonstrated
by overexpression of BRCA2 or a BRCA2 peptide that
binds p53 and significantly reduced p53-mediated apop-
tosis (25). Conversely, the direct association of p53 with
BRCA2 and RPA may interfere with HR independent of
p53 transcriptional activity. This is supported by evidence
that p53-mediated downregulation of replicative stress-
dependent HR required p53 interaction with RPA (27).
Here, we show that DBD-F directly binds p53TAD2
and ssDNA, and that both of these interactions are in-
hibited by FPA. FPA binding results in a conformational
shift in RPA occurring at a distant region from the
binding surface. These results denote a more interactive
relationship between DBD-F and other RPA domains
than previously thought (28). We provide evidence that
a double mutation (R41E and R43E) within DBD-F
prevents both p53 binding and helix destabilization
activity, suggesting that DBD-F may operate as a true
protein-DNA binding domain in vivo. Molecular
modelling simulations predict that DBD-F is highly
flexible and is therefore susceptible to structural change
due to ligand binding or subunit interactions. Finally,
using a set of structurally related compounds, we have
determined that both hydrophobic and electrostatic inter-




50 IRDye 700 labelled polyT-30mer and unlabelled polyA-
30mer oligonucleotides were purchased from Integrated
DNA Technologies, Inc. The N-terminal X-rhodamine
labelled p53TAD2, containing amino acids 40–57
(Xr-NH2-MDDLMLSPDDIEQWFTED), was produced
by AnaSpec. A p53TAD2 peptide containing an
hemagglutinin (HA) tag (NH2-MDDLMLSPDDIEQ
WFTEDYPYDVPDYA) that does not contain an
X-rhodamine label, referred to as p53TAD2-HA, was
produced by Thermo Scientific. FPA and structurally
related compounds were received from the Developmental
Therapeutics Program of the National Cancer Institute.
Cloning, expression and purification of RPA, p53 and
DBD-F fusion proteins
The human recombinant RPA and RPAF were purified
from Escherichia coli as described previously (29). RPA
containing the RPA70 mutations R41E and R43E, RPA







Figure 1. Illustration of the RPA heterotrimer depicting the oligonucleotide/oligosaccharide binding folds DBD-A through DBD-F. Modified from
image provided by Dr Marc Wold.
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site-directed mutagenesis kit (NEB), sequenced, and the
corresponding protein purified accordingly. The maltose-
binding protein (MBP) fusion protein containing amino
acids 1–168 of DBD-F, referred to as DBD-FMBP, was
created by cutting out a NcoI/PstI RPA70 fragment
from the RPA pET-11d vector, and ligating it into a
pMBP-parallel2 expression vector (30). The resulting
vector was expressed in E. coli, strain BL21, induced
with isopropyl b-D-1-thiogalactopyranoside (IPTG), and
purified using a gravity flow MBP-binding column (New
England Biolabs). The concentrations of purified proteins
were quantified using a Bradford assay. For expression of
p53–GST fusion protein and unmodified GST, Addgene
plasmid 10852 and pGEX-4T-1 were expressed in BL21
cells (31). After centrifugation, cells were sonicated in PBS
in the presence of 1mM PMSF and 1mM DTT, clarified
by centrifugation, and used directly in the binding assay.
Characterization of the purified proteins, p53 and GST
lysates, is shown in Supplementary Figure S4.
Electrophoretic mobility shift assays and helix
destabilization assays
Electrophoretic mobility shift assays (EMSAs) for RPA,
RPAF and RPA (R41E, R43E) were performed in
binding buffer B (25mM HEPES, 10% (v/v) glycerol,
10mM NaCl, pH 8.0). The ssDNA probe is a 50 IRDye
700 labelled polyT-30mer oligonucleotide. To make the
dsDNA probe, the labelled polyT-30mer was annealed to
a polyA-30mer and treated with mung bean nuclease as
reported previously (17). Concentrations of ssDNA and
dsDNA probes were 20 nM. Concentrations of RPA were
10 nM and 40 nM for ssDNA and dsDNAbinding, respect-
ively. The concentrations of the RPA mutants were
normalized relative to RPA ssDNA-binding activity.
EMSAs for the DBD-FMBP fusion protein were performed
in binding buffer A (25mM HEPES, 10% (v/v) glycerol,
100mMNaCl, pH 8.0) with 2 mMDBD-FMBP and electro-
phoresed at 4C. Gels were scanned on a near infrared
scanner, (LI-COR Biosciences).
Fluorescence anisotropy association curves
Data points were collected using a model A-1010 Alpha-
scan photon counting fluorometer (Photon Technologies)
in which the emission of the X-rhodamine-labelled
p53TAD2 was monitored in binding buffer A at 25C
upon titration with RPA or DBD-FMBP. The dye was
excited using a xenon short arc lamp (Ushio, UXL-
75XE, No. ME0282) followed by the excitation mono-
chromator set at 585 nm (bandpass of 5 nm). The
exciting beam passed through a rotatable polarizer con-
taining a mounted KN-36 Polaroid sheet (Polaroid) before
reaching the sample cuvet. Emitted light was collected at
630 nm (bandpass of 5 nm) after passing through a
similar second polarizer (analyzer) placed between the
sample cuvet and emission monochromator and photo-
multiplier (R928 PMT, Hamamatsu).
Each pair of intensity measurements, parallel (IVV) and
perpendicular (IVH), was collected after the reaction
reached equilibrium. The anisotropy values (<r>=
(IVVG·IVH) / (IVV+2·G·IVH), where G is the grating
factor (0.69 for X-rhodamine-labelled p53TAD2), reported
are averages of three independent values at each point in
the titration. For each intensity measurement, 30 data
points were collected over a 1-s time period, fit by linear
regression, and the fitted value at the midpoint, 0.5 s, was
the recorded value for that time interval and used in
determining the average over three such measurements.
When there was no change in fluorescence, only anisotropy
(<r>) was reported. Otherwise, the change in total fluor-
escence intensity (F, where F=IVV+2·G·IVH) or anisot-
ropy multiplied by fluorescence intensity (rF, where
rF=<r> · F) was used to determine a binding constant
(Ka) because these two functions are linear in concentra-
tions of fluorescent species. The fraction (Y) of p53TAD2
bound to RPA or DBD-FMBP was determined using the
appropriate average signal (<r>, F or rF), and the best
fit to a single binding site model (Equation 1) was
obtained by a least squares minimization where Ka
and<r> max are parameters. For instance,
Y ið Þ ¼ ð< r >obs ið Þ  < r >minÞ=ð< r >max  < r >minÞ
¼ ½ðRTðiÞ YðiÞ  PTðiÞÞ Ka=½1+Ka  ðRTðiÞ YðiÞ  PTðiÞÞ
ð1Þ
where <r>obs(i) is the average anisotropy at iteration i,
<r>min and <r>max are the minimum and maximum
anisotropies, RT is the total concentration of protein
(RPA or DBD-FMBP) and PT is the total concentration
of p53TAD2. Equation 1 can be rearranged into a quad-
ratic form (Equation 2):
0 ¼ Y2ið Þ Ka  PT ið Þ+Y ið Þ+Y ið Þ Ka  PT ið Þ
+Y ið Þ Ka RT ið Þ RT ið Þ Ka,
ð2Þ
where the quadratic coefficients are: a=Ka·PT, b= (1+
PT·Ka+RT·Ka), c=RT·Ka and Y can then be solved
using the familiar quadratic equation with the positive
sign proceeding the radical. Kd is the concentration of
free ligand at which Y=0.5 and Kd=1/Ka. When the
binding is weak and the concentration of fluorescent
ligand is low, Equation 1 can be simplified as shown in
Equation 3, also with two parameters, Ka and <r>max:
Y ið Þ ¼ ð< r >obs ið Þ  < r >minÞ=ð< r >max  < r >minÞ
 ½RT ið Þ Ka=½1+Ka RT ið Þ
ð3Þ
Parameter errors reported are one standard deviation.
For data sets with fewer than 20 points, the confidence
region was obtained by applying the Student’s t-test. The
concentrations were adjusted for any dilution effects.
Tryptophan fluorescence quenching
Quenching of tryptophan fluorescence was used to deter-
mine direct binding of FPA to RPA and aid in
determining whether both ligands could simultaneously
be bound to RPA. The fluorescence of the sample, 3 mM
RPA upon addition of FPA in binding buffer A at 25C,
was collected using the same apparatus as for the fluores-
cence anisotropy data, with an excitation wavelength of
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292 nm. For the emission wavelengths, a single value at
every 1 nm was collected from 325–375 nm and data were
smoothed using a Savitzky–Golay quadratic smoothing
function with a 7-point filter. The average of 5–8
smoothed buffer fluorescence intensity values at 348 nm
was subtracted from the average of 5–8 similarly
smoothed sample values and the difference for each
data point recorded (Fobs(i)). The data points were fit
according to the single binding site model (Equation 3)
with two parameters (Fmin and Ka), where Y(i)=1
 [(Fobs(i)Fmin) / (FmaxFmin)], Fobs(i) is the total
observed fluorescence at iteration i, Fmin and Fmax are
the minimum and maximum fluorescence respectively
and Y(i) is the fraction of RPA bound to FPA. The
reported Kd is calculated from Ka (Kd=1/Ka). The con-
centrations were adjusted for any dilution effects.
Fluorescence anisotropy competition curves
Data points were collected with the same apparatus and
method as described for the association curves where
X-rhodamine-labelled p53TAD2 is the reporter. Samples
were incubated after each addition of the competing
ligand at 25C until equilibrium was reached.
The data set was fit assuming the simplest model:
binding of p53TAD2 and FPA to the DBD-FMBP in the
full-length RPA is competitive and exclusive. A Newton–
Raphson matrix routine (32) for two nonlinear binding
equations and the associated Jacobian (J) embedded in a
two-dimensional least squares grid search was used to de-
termine two optimal and correlated Ka’s and the joint
68% confidence region for the competition experiment
involving RPA, p53TAD2 and FPA. Subsequently the
same procedure was followed for the DBD-FMBP using
both FPA and p53TAD2-HA as the competing ligands.
The Newton–Raphson was constrained by the conserva-
tion of the total concentrations of the three species
(Equations 4–6):
RT ið Þ ¼ R ið Þ  ð1+Ka1  P ið Þ+Ka2  FPA ið ÞÞ;R ið Þ ¼ RT ið Þ=L
ð4Þ
PT ið Þ ¼ P ið Þ+Ka1  P ið Þ R ið Þ ¼ P ið Þ G1 ið Þ,
where G1 ¼ 1+ðKa1 RT ið ÞÞ=L
ð5Þ
FPAT ið Þ ¼ FPA ið Þ+Ka2  FPA ið Þ R ið Þ ¼ FPA ið Þ G2 ið Þ,
where G2 ¼ 1+ðKa2 RT ið ÞÞ=L
ð6Þ
where RT, PT and FPAT are the total concentrations and
R, P and FPA are the free concentrations of RPA,
p53TAD2 and FPA, respectively, for each iteration (i),
L is the binding polynomial based on the simplest model
(1+Ka1 · P(i)+Ka2 · FPA(i)), and Ka1and Ka2 are the
binding constants of p53TAD2 binding to RPA and
FPA binding to RPA, respectively.
The above three conservation conditions reduce to two
equations (Equations 5 and 6) that generate the two
Newton–Raphson equations (Equations 7 and 8). F1
and F2, the concentrations of free p53TAD2 and FPA
respectively, equal zero when the concentrations are
correctly determined in the Newton–Raphson routine.
For instance,
F1 ið Þ ¼ PT ið Þ  P ið Þ G1 ið Þ ð7Þ
F2 ið Þ ¼ IT ið Þ  FPA ið Þ G2 ið Þ ð8Þ
The Jacobian matrix (Ji,j= qFi/qXj, X1= (P),
X2= (FPA)) is defined by J1,1=a, J1,2=b, J2,1= c and
J2,2=d. The four quantities are identified as:
a=G1+P(i) ·(Ka12·RT(i)) / L2, b=P(i) ·Ka1· RT(i)
·Ka2 / L2, c=FPA(i) ·Ka2 ·RT(i) ·Ka1 / L2, d=G2+
FPA(i) ·Ka22 ·RT(i) / L2. The inverse Jacobian matrix (J1)
is then: J11,1=d / , J
1
1,2=b / , J
1
2,1=c / 
and J12,2=a / , where delta is the determinant of
J (=a·d b·c).
The Newton–Raphson algorithm (Equation 9) uses
known values of PT(i), FPAT(i) and RT(i) and chosen
values of Ka1 and Ka2 where iterations (i) proceed to con-
vergence where F1=F2=0.
V i+1ð Þ ¼ V ið Þ  J
1  F ið Þ ð9Þ
where V is a column vector with rows P and FPA, and F is
a column vector with rows F1 and F2.
The optimal Ka1 and Ka2 values were used to calculate
the fraction of p53TAD2 bound to RPA and then con-
verted to a response function (Equation 10) in order to
determine the sum of squared residuals with respect to
<r>obs:
< r>calc ið Þ¼< r>min P ið Þ=PT ið Þ+< r>max ðPTðiÞ P ið ÞÞ=PT ið Þ
ð10Þ
The maximum or minimum signal in the absence of the
competing ligand was determined before titration.
Excellent endpoints were obtained using a conventional
double-reciprocal plot and refined using a one-
dimensional grid search added to the Newton–Raphson
routine. The square root of the minimum sum of the
squared residuals (sbest) was thus determined. Subsequent
grid searches were carried out varying the binding con-
stants until Equation 11 (33) was satisfied for the 68%
confidence boundary (s68%):
68 % ¼ best  ð1+ðp=ðn pÞÞ  Fp,np,0:32Þ
0:5
ð11Þ
with n data points, p parameters, and the critical F value
was calculated using an online F distribution calculator
(http://www.danielsoper.com/statcalc3/calc.aspx?id=4)
with p degrees of freedom in the numerator and (np)
degrees of freedom in the denominator. Significant
overlap between the 68% confidence regions of the indi-
vidually determined Kd values and the Kd values from the
competition experiment validates the assumption of the
competitive and exclusive binding model. Therefore,
the same program was used to analyse the competitive
binding data involving the DBD-FMBP. As the
DBD-FMBP does not have a tryptophan, direct binding
of FPA cannot be determined using tryptophan fluores-
cence quenching, and a competition experiment must be
used to determine the Kd for the binding of FPA to the
DBD-FMBP. The 68% ellipsoidal confidence region for the
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Kd values of p53TAD2/ DBD-F
MBP and FPA/
DBD-FMBP was truncated by the 68% confidence region
of the individually determined p53TAD2 and DBD-FMBP
Kd, leaving part of an ellipsoid as our final 68%
confidence region. The same analysis was used to deter-
mine the Kd and 95% confidence region (s95%=sbest *
(1+(p/(np)) *Fp, np, 0.05)
0.5) for the competitive binding
between X-rhodamine-labelled p53TAD2 and
p53TAD2-HA.
Protein modelling and docking
The protein structure (PDB ID: 2B29), composed of
residues 1–121 of RPA70, was relaxed using all-atom mo-
lecular dynamics (MD) simulations. All MD simulations
were performed using the GROMACS 4.5.1 package (34).
The AMBER96 force field (35) was used to describe the
protein structure and the tip3p water model to describe the
solvent (36). Protein charge states were set in accordance
with a pH of 7, and no counter ions were added (37). The
protein was solvated in a periodic dodecahedron-shaped
box with 5300 water molecules and energy minimized for
200 steps using the steepest descent algorithm. A 0.1-
ns-long position restrained MD simulation was followed
by a 1-ns-long MD simulation in the moles (N), volume
(V) and temperature (T) (NVT) ensemble. The tempera-
ture was maintained close to 300K by weak coupling to an
external temperature bath (38) with a coupling constant of
0.1 ps. The LINCS (39) algorithm was used to constrain
bond lengths within the solute. The SETTLE (40) algo-
rithm was used to constrain the bond lengths and the bond
angle in water. The integration time step was 2 fs. The
reaction field method (41) [reaction-field-zero as imple-
mented in GROMACS 4.5.1 (42)] was used to account
for electrostatic interactions with a twin-range cut-off of
0.9/1.2 nm. Interactions within the short-range cut-off
were evaluated at every step, whereas interactions within
the long cut-off were updated every five steps, together
with the pair list. The equations of motion were integrated
using the leapfrog algorithm. The snapshot at 1.0 ns from
the NVT simulation was used as input for the anisotropic
normal mode analysis (ANM) (43) calculation. The
all-atom ANM calculation was implemented using the
ProDy package (44), with a cut-off value of 15 Å and a
uniform force constant. The non-trivial three slowest
modes were used to generate a 200-conformer ensemble
within a root-mean-square value of 3.0 Å. Subsequently,
each conformer was energy minimized in the gas phase for
200 steps. The top 100 structures that displayed proper
stereochemistry were used in a docking simulation with
the structure for FPA using the virtual screening
software, PyRx, in conjunction with the docking
software, AutoDock Vina (45,46). Affinity scores in
PyRx are reported as binding energies (G), which were
then converted to apparent inhibitory constants (Ki)
through the equation, Ki=e
(G/RT), where T=
298.15K and R=0.001968 kcal/mol/K. The top scoring
DBD-F structure was compared with the original 2B29
structure in docking both FPA and a portion of the
p53TAD, 40MDDLMLSPDDI51, and graphically
reported using the software program Pymol (47).
Full length p53 binding assays
Clarified bacterial lysate (100 ml) expressing GST or p53–
GST was added to each well of a glutathione-coated 96
well plate (Pierce). After 30min, the plate was washed 3
with PBST (PBS, 0.1% tween-20), then incubated for
30min in PBS with 250 nM RPA. Plates were washed
3 with PBST and incubated with a polyclonal antibody
for GST (kindly provided by Dr James Wahl, 1:100), and
RPA70 (Bethyl, 1:1000) for 30min. Wells were washed 3
with PBS and incubated with secondary fluorescent
antibodies Alexa Fluor 680 (Invitrogen, 1:1000) and
Dylight 800 (ThermoScientific, 1:1000). Wells were
washed 3 with PBST and scanned on near infrared
scanner (LI-COR Biosciences). Binding efficiency was
determined by the amount of RPA signal normalized to
GST signal. Western blots of bacterial lysates are shown in
Supplementary Figure S4.
RESULTS
FPA, p53 and ssDNA compete for binding to RPA
We previously demonstrated that FPA prevented helix de-
stabilization by RPA (17). A potential explanation for the
loss of helix destabilization by RPA is that FPA binds to
DBD-F and prevents DBD-F–ssDNA intermediates from
forming before ssDNA binding by the high affinity DBDs.
To test this model, we separated RPA into two ssDNA-
binding entities, a heterotrimer without DBD-F (RPAF)
and DBD-F fused to MBP (DBD-FMBP). The capacity of
FPA to selectively inhibit ssDNA binding to DBD-FMBP
and not RPAF was observed via EMSA (Figure 2A and
B). MBP alone does not bind ssDNA (Supplementary
Figure S1A). Combined, these data indicate that the
mechanism of DNA unwinding by RPA is dependent on
DBD-F, and suggest that a peptide that mimics ssDNA,
such as p53TAD2, should also be an effective inhibitor of
helix destabilization. Indeed, an X-rhodamine-labelled
p53TAD2 peptide inhibited helix destabilization
(Figure 2C). p53TAD2 was not effective in preventing
the binding of RPA to ssDNA, indicating p53TAD2
does not compete with ssDNA for binding to the central
high affinity DNA binding core, DBD-A and B
(Figure 2D). The band observed directly above the free
dsDNA probe was determined to be due to the fluores-
cence of the X-rhodamine label of the p53TAD2 peptide
and does not interact with dsDNA or have helix destabil-
ization activity (Supplementary Figure S1B). These data
suggest that protein–protein interactions at the DBD-F
would have an effect on some aspect of DNA processing
by RPA, and that FPA can inhibit both types of sub-
strates, proteins and ssDNA, from interacting with the
DBD-F.
Effect of FPA analogues on RPA and DBD-F
MBP binding
With the evidence of FPA directly binding and inhibiting
the DBD-F, we attempted to determine the structural
components of this compound that are essential for
activity. A survey of the Open Chemical Repository
of the Developmental Therapeutics Program at the
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National Cancer Institute (NCI) identified seven struc-
tural analogues of FPA, referred to in the NCI
databank as NSC15520 (Figure 3A). All of the com-
pounds have at least three fused six-membered rings,
and three compounds have nearly exact structural back-
bones as that of FPA, but have substituted the
1,4-dicarboxylic acid with an anhydride (NSC204220),
a 1,4-diol (NSC49890), or a 1,4-dione (NSC2961)
(Figure 3A, #s 2, 4 and 5). The anhydride-containing
NSC98616 has a slightly altered backbone structure as
well as a hydroxyl group substituted for the singular
carboxyl group (Figure 3A, # 3). Also included in the
study were three abietic acid analogues (NSC4827,
NSC5007, NSC18746) (Figure 3A, #s 6, 7 and 8), as
abietic acid provides the backbone structure in the
reaction with fumaric acid to create FPA (48).
When assayed for helix destabilization activity, four
compounds (FPA, the diol-containing NSC49890, and
the anhydride compounds NSC204220 and NSC98616)
inhibited helix destabilization by RPA (Figure 3B, top
panel, lanes 1–4), but only FPA showed no evidence of
inhibiting RPA binding to ssDNA (Figure 3B, bottom
panel, lane 1). These data indicate that only FPA, with
the 1,4-dicarboxylic moiety, is capable of selectively in-
hibiting DBD-F of RPA, whereas the other compounds
(NSC204220, NSC98616, NSC49890) likely bind to
residues within the other DBDs, A–E. Abietic acid ana-
logues NSC4827, NSC5007 and NSC18746 showed no
effect on RPA helix destabilization and ssDNA binding,
suggesting that either the transition of abietic acid to a
nonplanar molecule, the addition of negatively charged
moieties, or both, are required for RPA inhibition.
NSC2961, a 1,4-dione, also did not interact with RPA,
accentuating the importance of the 1,4-dicarboxylic acid
for inhibition of DBD-F.
The binding of FPA and structural analogues of FPA to
DBD-FMBP was also investigated through fluorescent
anisotropy. Here, compounds were tested for the ability
to inhibit binding of p53TAD2 to DBD-FMBP. Of the
compounds tested, FPA showed the most potent inhib-
ition compared with the other seven compounds, further
supporting FPA as a DBD-F-specific inhibitor (Table 1).
Because the 1,4-dicarboxylic acid moiety appears to be
essential for the binding activity of FPA with DBD-FMBP,
we compared the specificity of FPA with other
1,4-dicarboxylic acids (Figure 3C). In these experiments,
both 1,4-cyclohexanedicarboxylic and succinic acids
(Figure 3C, compounds 1 and 2, respectively) are FPA
sub-structures. These three compounds were analysed
for their ability to inhibit the helix destabilization
activity of RPA (Figure 3D). As anticipated, FPA in-
hibited helix destabilization of a dsDNA template by
RPA, whereas 1,4-cyclohexanedicarboxylic and succinic
acids had no effect (Figure 3D, lane 3). To further
confirm the selective inhibition of FPA, we performed
competitive titration assays using fluorescence anisotropy.
Only FPA competed with X-rhodamine-labelled
p53TAD2 for binding to DBD-FMBP, as reported in
Table 1, with 1,4-cyclohexanedicarboxylic and succinic
acids showing no evidence of binding (data not shown).
Taken together, these results show that both the electro-
static charge of the dicarboxylic acid moiety and the
hydrophobic backbone of FPA are necessary for binding
to DBD-FMBP.
FPA and p53TAD2 directly bind to RPA independently
and competitively
The ability of FPA to inhibit DBD-F binding to ssDNA
suggested, but did not prove, a direct interaction of FPA
with full length RPA. To assess direct binding to full
length RPA, we determined the ability of FPA to
quench tryptophan residues within RPA (Table 2,




Figure 2. p53TAD2 and FPA bind to DBD-FMBP and RPA and affect DNA binding. For (A–D): Lane with DNA probe in the absence of RPA is
denoted by ‘P’. ssDNA–RPA binding without FPA is marked by a (-). Concentration of labelled DNA probe is 10 nM. For (A) and (B), the
concentration of FPA is 300, 100, 30, 10, 3, 1 mM, respectively. (A) Lack of inhibition of ssDNA–RPAF formation in the presence of FPA as
determined by EMSA. The concentration of RPAF is 20 nM. (B) Inhibition of ssDNA–DBD-FMBP binding by FPA. The concentration of the
DBD-FMBP is 2 mM. For (C) and (D), the p53TAD2 concentration is 24, 12, 6, 3, 1.5 mM, respectively. (C) Inhibition of helix destabilization by
p53TAD2. The amount of helix destabilization was determined by the appearance of an upward shifted band consisting of RPA bound to unwound
ssDNA derived from dsDNA. Lane with labelled DNA and p53TAD2 in the absence of RPA is denoted by a ‘*’. (D) Lack of inhibition of ssDNA–
RPA binding by p53TAD2. The p53TAD2 peptide can be detected at higher concentrations due to the fluorescence of the x-rhodamine label, and
does not bind DNA, as determined in figure S3C.
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RPA resulted in the quenching of the fluorescence of one
or more tryptophan residues within RPA, allowing the
binding constant of FPA to RPA to be determined
(Kd=29.0±3.5mM). DBD-F itself does not contain
tryptophan residues. Therefore, these data do not
confirm direct binding to DBD-F itself; however, based
on our previous data (17) and the other data presented
here, it suggests that the quenching of tryptophan by FPA
in RPA is likely due to a conformational change induced
by direct binding, and not by a direct interaction of tryp-
tophan with the inhibitor.
To assert that p53TAD2 and FPA compete for the same
binding site, we conducted fluorescence anisotropy
titrations. We observed X-rhodamine-labelled p53TAD2
bound to RPA (Supplementary Figure S2A). In a
competition assay, addition of FPA to a preformed
p53TAD2–RPA complex resulted in a decrease in anisot-
ropy, indicating that FPA bound to RPA, replacing
p53TAD2 (Supplementary Figure S2B). A Newton–
Raphson matrix routine for two nonlinear binding equa-
tions was embedded in a two-dimensional least squares
grid search in order to determine the two optimal
binding constants and determine the joint 68% confidence
region for FPA (Kd=29.0±3.5 mM) and p53TAD2
(Kd=6.06±0.08 mM). Increasing concentrations of
FPA up to 275 mM showed no evidence of binding to
p53TAD2 (Supplementary Figure S3A). The competition
experiment showed no evidence for joint occupancy of
p53TAD2 and FPA in the DBD-F of the full length
RPA, and was determined to be a valid method for
determining the affinity of a ligand by replacement of a




Figure 3. Effect of structural analogues of FPA on DBD-FMBP inhibition. (A) Structures of lead compound FPA and structural analogues used in
this study. (B) Effect of FPA-related compounds on DNA binding as measured by EMSAs. 200 mM of each compound was used. Top panel: addition
of dsDNA to compounds preincubated with RPA. Bottom panel: addition of ssDNA to compounds preincubated with RPA. Lane with DNA in the
absence of RPA is demarked by ‘P’. RPA–DNA binding without inhibitor is marked by a (-). Numbers correspond to structures in ‘A’. (C) Structure
of FPA sub-structures succinic acid, 1,4-cyclohexanedicarboxylic acid and FPA (1–3, respectively). (D) Effect of compounds in ‘C’ (200 mM) on
helix destabilization via EMSA. Lane with ssDNA probe in the absence of RPA is demarked by ‘P’. RPA–DNA binding without inhibitor is denoted
by a (-).
Table 1. Kd values for FPA and derivatives binding to DBD-F
MBP
prebound to p53TAD2 as determined by fluorescence anisotropy
# Inhibitor Kd (mM) SD (mM)
1 FPA 9.0 1.2
2 NSC204220 103 9
3 NSC98616 ND ND
4 NSC49890 ND ND
5 NSC2961 ND ND
6 NSC4827 ND ND
7 NSC5007 ND ND
8 NSC18746 660 250
ND, not determined.
Nucleic Acids Research, 2013, Vol. 41, No. 3 2053
that FPA binds directly to RPA, and that both FPA and
p53TAD2 bind RPA independently and competitively.
p53TAD2 and FPA bind specifically to the DBD-F of
RPA
To ensure that the competition between FPA and
p53TAD2 for RPA is specific for DBD-F, their respective
binding to DBD-FMBP was explored. The p53TAD2
bound to DBD-FMBP with high affinity (Kd of 1.03±
0.25mM) as determined by fluorescence quenching of the
X-rhodamine label (Table 2 and Supplementary Figure
S2D, filled circles). Addition of MBP to p53TAD2 gave
no change in fluorescence under similar concentrations
(Supplementary Figure S2D, hollow circles). These
results showed that the isolated DBD-FMBP is compe-
tently folded for binding protein.
FPA binding to DBD-F could not be detected directly,
as there were no tryptophans in DBD-F. Therefore, a
fluorescence anisotropy competition assay was used to de-
termine the affinity of FPA for DBD-FMBP. The fraction
of p53TAD2-bound DBD-FMBP decreased upon addition
of FPA (Supplementary Figure S2E). From these findings,
the two binding constants for both ligands were
determined to be Kd values at 1.2 and 9.0 mM, respectively
(Table 2 and Supplementary Figure S2F).
In comparison with full length RPA, DBD-FMBP had
substantially higher affinity for both p53TAD2 and FPA
than the full length RPA (6-fold and 3-fold, respectively).
A similar competition experiment involving X-rhodamine-
labelled p53TAD2 and p53TAD2-HA showed that the Kd
values for binding DBD-FMBP were not significantly dif-
ferent at the 95% confidence level. Therefore, the presence
of the X-rhodamine dye on the N-terminus of p53TAD2
did not significantly alter binding (Kd=0.67mM, data not
shown). Furthermore, the critical amino acids for contact-
ing the DBD-F are indeed within the p53TAD2, as
addition of the 10 amino acids of the HA tag did not
alter binding.
R41E and R43E mutations in RPA70 reveal the specific
nature of DBD-F for protein, DNA and FPA
Evidence for the requirement of DBD-F in recombination
was first derived from the yeast strain rfa-t11, containing a
K45E mutation in Rfa1, the yeast homolog of RPA70
(49). Although it has been inferred that the mutation
causes the interruption of RPA with several RPA sub-
strates such as p53, only Ddc2, the yeast homolog of
ATRIP, has been shown to be directly affected by the
mutation using full length proteins (50), and protein–
protein interaction studies involving full length human
RPA with analogous mutations to rfa-t11 have not been
demonstrated. To confirm that FPA interactions with
human RPA are specific to the analogous K45 mutation
of rfa-t11, we generated a glutamic acid-substituted
mutant (R41E, R43E), as NMR studies have indicated
that both residues are essential for p53TAD2 binding (51).
The double mutant retained the ability to bind ssDNA,
as no amino acid substitutions were made on the
high-affinity DBDs (Figure 4A, left panel). When tested
for helix destabilization activity, the mutant was limited in
unwinding DNA, similar to RPAF (Figure 4A, right
panel). The small amount of unwinding observed was
not further inhibited by FPA at concentrations up to
1mM, suggesting that the nominal unwinding that does
occur by RPA (R41E, R43E) is DBD-F independent. The
R41E and R43E mutations highlight their importance in
helix destabilization, and strongly suggest that the recom-
bination deficient rfa-t11 yeast strain likewise contains an
RPA that is deficient in this activity.
To determine whether the RPA (R41E, R43E) mutation
has an effect on p53 binding, we devised an ELISA-based
binding assay (Figure 4C and D). Wild-type RPA bound
readily to the immobilized p53–GST fusion protein, and
was effectively inhibited from binding to p53 by FPA at
100 mM. GST alone does not bind RPA (Supplementary
Figure S3B). In a comparison of RPA, RPAF and RPA
(R41E, R43E), only RPA was capable of effectively
binding p53–GST. These data support R41 and R43 as
essential residues in DBD-F for p53 binding.
We then tested whether RPA (R41E, R43E) would
undergo tryptophan quenching in the presence of FPA
(Table 2 and Figure 4E). Half-maximal quenching was
seen at a concentration of 230 mM, approximately 8-fold
higher concentration than required for RPA. This suggests
that the double mutation affects the ability of RPA to
change conformation in the presence of FPA, providing
further evidence of FPA specificity for DBD-F.
Modelling of the DBD-F reveals large scale changes
within the basic cleft
The ability of DBD-F to bind several disparate ligands
(ssDNA, FPA, proteins) suggests that the domain
possesses structural and dynamic features. Recent work
suggests that conformational changes at the binding site
are often responsible for the ability of proteins to bind
different ligands (52,53). Using MD simulations, we
determined the extent by which DBD-F is susceptible to
conformational change (Figure 5). The original crystal
structure of DBD-F shows a wide gap within the basic
cleft, with the walls of the cleft opening outward,
creating a large area for binding (24) as represented in
Figure 5A. However, when analysed by docking
software, FPA was predicted to bind with low affinity
(Ki=204.7 mM) at a position adjacent to the cleft.
Table 2. Kd values of DBD-F
MBP and various RPAs for RPA and
p53TAD2 substrates as determined by either fluorescence quenching
or fluorescence anisotropy
Protein Substrate Kd (mM) SD (mM) Method
a
RPA FPA 29.0 3.5 1
RPA p53TAD2 6.06 0.08 2
DBD-F p53TAD2 1.03 0.25 1
DBD-F FPA 9.0 1.2 2
RPAF FPA >400 NA 1
RPA(R41E,R43E) FPA 230 18 1
DBD-Fb p53TAD2 99.9 8.4 2
DBD-Fb FPA 18.3 0.9 2
a(1)Fluorescence quenching; (2)Fluorescence anisotropy.
bFrom Souza-Fagundes et al. (63).
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A portion of the p53TAD2 predictively bound at higher
affinity (Ki=24.5 mM), but does not lie in line with the
basic cleft of DBD-F (Figure 5A).
When MD simulations were used to find alternative
conformations of the DBD-F, a DBD-F representation
predicted to bind FPA at 18-fold greater affinity was
found (Ki=11.3mM) (Figure 5B). This representation
possessed a basic cleft in a more restricted conformation,
with the walls of the cleft almost wrapping around the
inhibitor. The p53TAD2 peptide also was predicted to
bind at 8-fold higher affinity (Ki=2.9 mM) than to the
original crystal structure of DBD-F, enveloping the pre-
dicted binding site of FPA. Though the docking scores
should be considered as a relative ranking parameter,
they do suggest that the newly ascribed DBD-F represen-
tation may be more accurate than the original crystal
structure. This new representation of DBD-F may help
to explain the exclusive binding of dissimilar ligands and
provide a more accurate model for DBD-F in vivo.
DISCUSSION
The ability of multiple ligands to bind DBD-F is an
example of DNA and protein mimicry common to DNA
repair pathways, allowing RPA to ‘hand-off’ multiple
DNA and protein substrates (54). RPA–p53 interactions
are required for maintaining a balance between pathways
that repair double strand breaks, as mutations in the





Figure 4. The K41E,K43E mutation affects RPA binding to protein, DNA and FPA. (A) Left panel: wild-type RPA and two mutant RPAs are all
capable of competently binding ssDNA via EMSA. Right panel: only wild-type RPA is capable of effectively unwinding dsDNA. (B) The small
amount of dsDNA that is unwound by RPA (R41E, R43E) is not effected by moderate concentrations of FPA. Concentrations of FPA are 31, 62,
125, 250, 500, 1000mM, respectively. (C) ELISA-based assay showing the ability of FPA to prevent p53 binding to full length RPA. Bacterial lysates
expressing p53–GST were bound to a glutathione-coated plate, and then incubated with 250 nM RPA in the presence of the indicated concentration
of FPA. 100% RPA signal is normalized to wells with 0 mM inhibitor. 0% RPA signal is normalized to the absence of RPA (0*). Error bars represent
the standard error of the mean. (D) RPA(R41E, R43E) and RPAF are unable to bind p53 as determined by assay described in ‘A’. (E) Tryptophan
quenching of RPA(K41E,K43E) by FPA. Kd=230mM±18 mM.
Figure 5. Docking simulations of a crystal structure of DBD-F
and conformer optimized for FPA binding. For both structures,
FPA is shown in stick form, whereas the p53TAD2 sequence
‘MDDLMLSPDDI’ is represented by a ribbon structure. (A) The
original crystal structure of DBD-F docked to FPA and p53TAD2
[5.5 and 4.4 kcal/mol (24.5 mM and 204.7mM), respectively]. (B) A
DBD-F model optimized for FPA binding docked FPA and p53TAD2
[6.6 and 5.9 kcal/mol (2.9 mM and 11.3 mM), respectively].
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excessive homologous recombination (55). This hyper-
recombination phenotype can lead to genomic instability
and cell death (56,57). An inhibitor to the DBD-F may
have a similar destabilizing effect on cancer cells to that of
the p53TAD2 mutant. As other proteins involved in hom-
ologous recombination also bind the DBD-F such as
Mre11 and Nbs1 (10,14), it is likely that a DBD-F inhibi-
tor, such as FPA, could have the ability to deregulate
homologous recombination, allowing the selection of
normal cells that have competent and redundant DNA
repair pathways over cancer cells that typically have
reduced DNA repair capacity.
Two components of FPA appear to be essential for the
inhibition of DBD-F. The dicarboxylic moiety of FPA
likely interacts with the positively charged residues of
the DBD-F, R41 and R43, as removal or alteration of
the moiety to hydroxyl, aldehyde or anhydride eliminates
either the action or specificity of the compound to
DBD-F. The backbone of FPA, derived from abietic
acid, provides a complex hydrophobic helical structure
that likely fits within the hydrophobic residues of
DBD-F. The negatively charged and hydrophobic compo-
nents of FPA combine to resemble both the ssDNA and
peptide substrates of DBD-F. Further studies will entail
modifications in both charged and uncharged components
of FPA in newly synthesized compounds that allow for
higher specificity and affinity to the DBD-F.
Tryptophan fluorescence quenching has been used pre-
viously to determine changes in RPA conformation upon
phosphorylation of the N-terminal domain of RPA32
(58–61). By assessing tryptophan quenching of RPA by
FPA and subsequent fluorescence anisotropy competition
assays, we demonstrate that FPA binds the DBD-F of
RPA. Additionally, the comparison of tryptophan fluor-
escence quenching of full-length RPA, RPAF and the
RPA (R41E, R43E) mutant in the presence of FPA
provide evidence that FPA induces a structural rearrange-
ment involving DBD-F and DBDs A–E. We currently do
not know which of the eight tryptophan residues in DBDs
A–E that are quenched upon FPA binding. However,
ssDNA is capable of quenching four residues that reside
in the DBDs A–D, W212, W361, W528 and
W107(RPA32), respectively, (58) and our data shows
that FPA does not affect ssDNA binding of RPA,
making those residues less viable candidates for quenching
by FPA-bound DBD-F. This suggests that W197, W414,
W442 or W2 (RPA32) are quenched by FPA binding.
FPA-induced conformational change is further supported
by our data that revealed a difference in ligand binding to
DBD-FMBP compared with full length RPA. This was ini-
tially an unexpected result, as the flexibly linked DBD-F
on RPA and the DBD-FMBP should have the same affinity
to ligand if DBD-F is a truly independent domain.
Combined, our data imply an interaction between
DBD-F and other RPA domains without preventing
those same domains from binding to ssDNA
(Figure 6A). We have previously shown FPA does not
affect ssDNA binding to RPA (17), nor does p53TAD2
affect RPAF binding to ssDNA (Figure 3D), consistent
with previous findings that full-length p53 did not inhibit
RPA binding to ssDNA (62). These data, and the
observed binding affinity differences of ligand to
Figure 6. (A) Comparison of Kd values for p53 peptides and FPA binding to DBD-F and RPA. Solid and hollow circles are p53TAD2 and FPA Kd
values, respectively, determined in this study. Solid and hollow triangles are p53TAD2b [15 aa peptide (aa 43–57 of p53)] and FPA Kd values,
respectively, as reported in previous literature and therein denoted by (y)(63). (B) Depiction of competition between p53TAD2 and an inhibitor for
the DBD-F accompanied by a change in conformation.
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DBD-FMBP and RPA, suggest that conformational
changes occur in DBD-F in proximity to other RPA
domains without affecting ssDNA binding of core
domains DBD-A and DBD-B.
The RPA (R41E, R43E) mutation not only links the
loss of RPA–p53 interaction to the loss of recombination
in the rfa-t11 yeast strain, but also raises the possibility
that the helix destabilization activity of RPA may have
relevance in vivo. RPA is commonly used in in vitro
based recombination studies, initially binding ssDNA,
and is eventually replaced by Rad51 before recombination
with homologous dsDNA. Although RPA is thought to
serve merely to deconvolute the ssDNA substrate before
Rad51 binding, there could be a DBD-F–ssDNA inter-
mediate step that is essential for efficient recombination
to occur. The K45E mutation in rfa-t11 has a deficit in
catalysing recombination in these assays, which has been
attributed to a loss of protein–protein binding (7). We
suggest that both protein–protein and protein–DNA inter-
actions with DBD-F may be important in the recombin-
ation process.
The crystal structure of the DBD-F, valuable as it has
been for determining the spatial organization of the
domain, offers only one conformation within a wide
range of possible conformations. We previously used this
crystal structure to model FPA and Rad9 binding to
DBD-F (17); however, the molecular docking of FPA pre-
dicted an affinity that was much lower than the actual
in vitro binding affinity. By determining an optimal
binding conformation towards FPA, we demonstrate how
the basic cleft of the DBD-F changes shape dramatically to
confine the ligand. Multiple conformational changes are
possible that are initiated by different ligands, as well as
DBD-F contact with the remainder of RPA. Based on the
relative binding parameters of the new conformation of
RPA towards FPA, we are more confident in using this
model to identify new inhibitors of DBD-F in silico.
Competition displacement studies of a similar p53
fragment and FPA have been reported (63). The reported
binding constant reflected markedly weaker binding,
100 mM vs. 1 mM for p53TAD2 (Figure 6B). For FPA,
the binding constant was also reported as weaker (18mM
vs. 9 mM). Although we can appreciate differences in
apparent binding due to small changes in peptide
sequence and assay conditions, we cannot account for the
50-fold difference in the ratios of binding constants
(FPA:p53TAD2 peptide) between these two studies.
The involvement of RPA in several DNA modulatory
activities hinges upon its ability to bind multiple disparate
substrates. Many of these activities are dependent on the
versatility of DBD-F, which offers a binding site for both
protein and ssDNA, and harbours a site necessary for
DNA unwinding. Further study with FPA and DBD-F
may resolve more in-depth aspects of RPA in DNA meta-
bolic activities.
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